Immunosequencing, the science of profiling T- and B-cell receptors, has been widely used to understand how the adaptive immune system changes in various disease states and how different treatment modalities impact immune responses. Dr. Matthew Knight will present the key principles behind the immunoSEQ® Technology that utilizes a proprietary bias-controlled sequence quantitation method. Recently published data will be presented to illustrate the power of immunosequencing in a variety of infectious disease models, including COVID-19. In addition, Dr. Knight will present the immunoSEQ® T-MAPTM COVID data set that can help researchers evaluate antigen-specific T-cell responses to SARS-CoV-2 proteins in the context of natural infection or vaccine research.
Matt Knight, PhD.
Scientific Liaison, Adaptive Biotechnologies
Presentation followed by LIVE Q&As